Intellego and Shanghai Zhongyou Medical High-Tech Co., Ltd (Likang) are significantly expanding their existing collaboration with a new deal poised to reshape the healthcare market across several Asian countries. The agreement, valued between $360 million and $1.4 billion over the next five years, builds upon the success of their earlier ventures.
This expansion follows positive results from the distribution of Intellego’s dosimeter products, prompting the partners to not only accelerate deliveries within China but also to extend their collaboration to additional markets. Under the new agreement, Intellego has granted Likang exclusive sales and marketing rights for two specific UVC disinfection products designed for the healthcare sector, targeting Japan, South Korea, Singapore, Thailand, Indonesia, and Malaysia. This exclusivity is linked to a minimum sales volume of $360 million, though the ultimate value could reach higher levels depending on the specific mix of products sold.
The implementation of this deal is contingent upon market approval from regulatory bodies and adherence to standard terms, including product quality. However, the involved parties anticipate minimal regulatory hurdles, given the low-risk classification of the products and the existing documentation.
The sales volume targets are scheduled to be met over a five-year period, commencing with a phased rollout. The partners anticipate the first revenue from the project in 2025.
Zhongyou Medical (Likang) is a subsidiary of Jiangsu Yuyue Medical Equipment and Supply Co., Ltd, a company listed on the Shenzhen Stock Exchange. Likang holds a leading position as a distributor, supplying a diverse range of disinfectant products to over 3,000 hospitals throughout China.
Jiangsu Yuyue Medical Equipment and Supply Co., Ltd boasts a comprehensive global network comprising twelve research and development centers and nine production bases spread across strategic locations, including Shanghai, Shenzhen, Nanjing, Suzhou, Danyang, Tibet, as well as international sites in the Netherlands, Germany, and Italy. Their global presence supports over 300,000 medical institutions across 131 countries and regions, reaching an estimated 300 million households worldwide. For more information, please visit the company’s website: Yuwell Website
